The other option is to grant EUA with limitations depending on the data until further review. When the data is broken down and mortality is looked at with the Leronlimab patients there may be trends with those who had a high level of survival and conversely , those who had a higher level of dying, based on the 28 days. So do you continue to crunch data and delay an EUA with limitations then after reviewing 60 day data take an additional step ? Right now we are all speculating but the fda needs a win here in the mortality space and we are probably the closest thing to it.